A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.
A new clinical trial will test whether an experimental vaccine can help patients' immune systems to stop the spread of deadly glioblastoma brain cancer.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
Researchers have developed a new approach that uses microRNA in combination with chemotherapy to help treat glioblastoma brain cancer. In preclinical models, the approach increases survival of the deadly brain cancer five fold.